JC
Therapeutic Areas
Salarius Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pan-Coronavirus Fusion Inhibitor | Prophylaxis & treatment for all human coronaviruses (SARS-CoV-2, endemic coronaviruses) | Preclinical |
| Broad Respiratory Antiviral (Tripledemic Inhibitor) | Prophylaxis & treatment for Influenza, COVID-19, and RSV | Discovery |
| GPCR-Targeted Conjugates | GI tumors, including colorectal cancer | Discovery |
Leadership Team at Salarius Pharmaceuticals
RP
Rick Pierce
Chief Executive Officer
BH
Barb Hibner
Chief Scientific Officer
PM
Peter Marschel
Chief Business Officer
ML
Michael Lipp
Chief Technology Officer
MR
Mark Rosenblum
Chief Financial Officer
AY
Annie Yan
Corporate Controller
WM
William McVicar
Chairman of the Board
DJ
David J. Arthur
Board Member
JL
Jonathan Lieber
Board Member
TB
Tess Burleson
Board Member